Table 1 Demographics and clinical data for study participants

Age-at-analysis, years

47 (11, 24–64)

35 (9, 22–57)^b

52 (4, 45–60)

52 (5, 42–62)

% Female

60%

40%

42%

38%

% Mild or moderate ID

0%

83%

79%

67%

CAMCOG score^a

NA

80/107 (11, 55–96, n = 31)

70/107 (13.8, 41–92, n = 11)^c

59/107 (13.9, 39–87, n = 10)^c

mCRT score (immediate)^a

NA

35/36 (1.5, 30–36, n = 30)

20/36 (11.2, 0–36, n = 12)^c

15/36 (7.9, 0–32, n = 11)^c

mCRT score (delayed)^a

NA

12/12 (0.9, 8–12, n = 31)

6/12 (3.8, 0–12, n = 13)^c

4/12 (3.3, 0–12, n = 11)^c

CSF Aβ_42:40 ratio

0.11 (0.01, 0.08–0.12)

0.09 (0.02, 0.04–0.12)^b

0.05 (0.01, 0.03–0.08)^b

0.05 (0.01, 0.04–0.08)^b

CSF p-tau pg/ml

36 (8, 22–54)

35 (24, 10–122)

145 (86, 22–304)^b

158 (82, 31–323)^b

CSF t-tau pg/ml

243 (57, 167–366)

295 (166, 86–671)

936 (658, 118–2565) ^b

959 (500, 212–1988) ^b

CSF NFL pg/ml

NA

355 (234, 65–1036)

1071 (767, 313–3123)

1387 (832, 627–3957)